<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926962</url>
  </required_header>
  <id_info>
    <org_study_id>W 4873 01</org_study_id>
    <nct_id>NCT03926962</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability And Pharmacokinetics Of Single Ascending Doses And The Effect Of Food On Oral WCK 4873 In Healthy Adult Volunteers</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Ascending Doses And The Effect Of Food On Oral WCK 4873 In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled study, consisting of a single
      ascending dose (SAD) part and a 2-way crossover food effect (FE) part. Each subject will
      participate in only one cohort during the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2013</start_date>
  <completion_date type="Actual">July 13, 2013</completion_date>
  <primary_completion_date type="Actual">June 25, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing incidence of treatment emergent AEs</measure>
    <time_frame>Day 18</time_frame>
    <description>Incidence of treatment emergent AEs, abnormal clinical laboratory findings, variations in LFTs, abnormal physical examination findings, variations in vital signs and variations in 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating PK parameters for profiling</measure>
    <time_frame>Day 4</time_frame>
    <description>plasma PK parameters -Area under curve (AUC0-t, AUC0-12, AUC0-24, AUC0-inf, %AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating PK parameters for profiling</measure>
    <time_frame>Day 4</time_frame>
    <description>plasma PK parameters- maximum concentration (Cmax, Clast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating PK parameters for profiling</measure>
    <time_frame>Day 4</time_frame>
    <description>plasma PK parameters tmax, tlast, kel, tÂ½,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating PK parameters for profiling</measure>
    <time_frame>Day 4</time_frame>
    <description>urine PK paramters (Aeurine)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating PK parameters for profiling</measure>
    <time_frame>Day 4</time_frame>
    <description>feces PK paramters ( Aefeces)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating PK parameters for profiling</measure>
    <time_frame>Day 4</time_frame>
    <description>PMN white blood cell concentrations of WCK 4873.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>WCK 4873</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Visually matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WCK 4873</intervention_name>
    <description>100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)</description>
    <arm_group_label>WCK 4873</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Visually matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI : 18-30 kg/m2 (Body Mass Index [BMI] [kg/m2] = Body weight [kg] Height2 [m2])

          -  Ability and willingness to abstain from alcohol, methylxanthine-containing beverages
             or food (coffee, tea, cola, chocolate, &quot;powerdrinks&quot;), grapefruit (juice) from 48 h
             prior to entry in the clinical research center until discharge

          -  Medical history without major pathology

        Exclusion Criteria:

          -  Evidence of clinically relevant pathology

          -  Mental handicap

          -  History of relevant drug and/or food allergies

          -  Regular/routine treatment with non-topical medications within 30 days prior to entry
             into the clinical research center

          -  Smoking within 60 days prior to drug administration and through the follow-up visit

          -  History of alcohol abuse or drug addiction (including soft drugs like cannabis
             products)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

